<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Vasodilators: peripheral; Peripheral vascular disease; Intermittent claudication; Naftidrofuryl; Cilostazol; Raynaud’s syndrome; Nifedipine; Inositol nicotinate" /><meta name="IX" content="Vasodilators: peripheral; Peripheral vascular disease; Intermittent claudication; Naftidrofuryl; Cilostazol; Raynaud’s syndrome; Nifedipine; Inositol nicotinate" /><title>2.6.4 Peripheral vasodilators and related drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="27021.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="27021.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=27021.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2614.htm">2.6 Nitrates, calcium-channel blockers, and other antianginal drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="202731.htm" title="Previous: RANOLAZINE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="119724.htm" title="Next: CILOSTAZOL">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_27021">2.6.4 Peripheral vasodilators and related drugs</h1><?highlighter on?><div id="pC" class="jN"><div><p>Peripheral
vascular disease can be either occlusive (e.g. <i>intermittent claudication</i>) in which occlusion of the peripheral arteries is caused by atherosclerosis,
or vasospastic (e.g. <i>Raynaud’s syndrome</i>).</p><p>Peripheral arterial occlusive disease is associated with an
increased risk of cardiovascular events; this risk is reduced by measures
such as smoking cessation (<a title="BNF:sub-section: Cigarette smoking" href="3689.htm#_3689">section 4.10.2</a>), effective control of blood
pressure (<a title="section: Hypertension and heart failure" href="2534.htm#_2534">section 2.5</a>), regulating blood lipids (<a title="section: Lipid-regulating drugs" href="2836.htm#_2836">section 2.12</a>), optimising glycaemic control
in diabetes (<a title="section: Drugs used in diabetes" href="4080.htm#_4080">section 6.1</a>), taking aspirin in a dose of 75 mg
daily (<a title="section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>), and possibly weight reduction
in obesity (<a title="section: Drugs used in the treatment of obesity" href="3381.htm#_3381">section 4.5</a>). Exercise
training can improve symptoms of intermittent claudication; revascularisation
procedures may be appropriate.</p><div id="_215683"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Cilostazol, naftidrofuryl oxalate, pentoxifylline
and inositol nicotinate for the treatment of intermittent claudication
in people with peripheral arterial disease (May 2011)</h3><p>Naftidrofuryl oxalate is an option for the treatment of intermittent
claudication in patients with peripheral arterial disease in whom
vasodilator therapy is considered appropriate.</p><p>Cilostazol, pentoxifylline, and inositol nicotinate are not
recommended for the treatment of intermittent claudication in patients
with peripheral arterial disease; patients currently receiving these
treatments should have the option to continue until they and their
clinician consider it appropriate to stop.</p></div></div><p><b>Naftidrofuryl</b> can alleviate symptoms of intermittent
claudication and improve pain-free walking distance in moderate disease.
Patients taking naftidrofuryl should be assessed for improvement after
3–6 months.</p><p><b>Cilostazol</b> is licensed for use in intermittent claudication to improve walking
distance in patients without peripheral tissue necrosis who do not
have pain at rest (but see NICE guidance above). Patients receiving
cilostazol should be assessed for improvement after 3 months. The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (October 2005) that cilostazol is not recommended for
the treatment of intermittent claudication within NHS Scotland.</p><p>Inositol nicotinate and pentoxifylline are not established as
being effective for the treatment of intermittent claudication.</p><div id="_27021.1"><p>Management
of <i>Raynaud’s
syndrome</i> includes avoidance of exposure to cold and stopping
smoking. More severe symptoms may require vasodilator treatment, which
is most often successful in primary Raynaud’s syndrome. <b>Nifedipine</b> (<a title=" Calcium-channel blockers" href="2616.htm#_2616">section 2.6.2</a>) is useful for reducing the frequency
and severity of vasospastic attacks. Alternatively, <b>naftidrofuryl</b> may produce symptomatic improvement; <b>inositol nicotinate</b> (a <span>nicotinic acid</span> derivative) may also be considered. Pentoxifylline, <span>prazosin</span>, and moxisylyte
are not established as being effective for the treatment of Raynaud’s
syndrome.</p></div><p>Vasodilator therapy is not established as being
effective for <i>chilblains</i> (<a title=" Topical circulatory preparations" href="6447.htm#_6447">section 13.13</a>).</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_119724"><a href="119724.htm" title="CILOSTAZOL">CILOSTAZOL</a></li><li id="_2712"><a href="2712.htm" title="INOSITOL NICOTINATE">INOSITOL NICOTINATE</a></li><li id="_2718"><a href="2718.htm" title="MOXISYLYTE">MOXISYLYTE</a></li><li id="_2725"><a href="2725.htm" title="NAFTIDROFURYL OXALATE">NAFTIDROFURYL OXALATE</a></li><li id="_2716"><a href="2716.htm" title="PENTOXIFYLLINE">PENTOXIFYLLINE</a></li><li id="_2720"><a href="2720.htm" title="Other preparations used in peripheral vascular disease">Other preparations used in peripheral vascular disease</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="202731.htm">Previous: RANOLAZINE</a> | <a class="top" href="27021.htm#">Top</a> | <a accesskey="]" href="119724.htm">Next: CILOSTAZOL</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>